Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (9) , 1302-1310
Abstract
Paraneoplastic neurological syndromes (PNSs) are neurological disorders occurring in the context of an underlying tumor.1 These disorders are immune mediated and associated with cancer-induced immune responses, including neuronal autoantibodies..2 Small cell lung cancer (SCLC) is the most frequent cancer associated with PNS, but non–small cell lung cancer (NSCLC) is also commonly found in patients with PNS.3 In a prospective study of 264 patients with SCLC, almost 10% developed a PNS, and many patients, even those without a diagnosis of PNS, had 1 or more neuronal autoantibody.4Keywords
This publication has 29 references indexed in Scilit:
- Neuronal autoantibodies associated with cognitive impairment in melanoma patientsAnnals of Oncology, 2019
- High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patientsJournal of Neurology, 2017
- Paraneoplastic neurologic disorders in small cell lung carcinomaNeurology, 2015
- Cognitive and Brain Structural Changes in a Lung Cancer PopulationJournal of Thoracic Oncology, 2015
- High prevalence of NMDA receptor IgA/IgM antibodies in different dementia typesAnnals of Clinical and Translational Neurology, 2014
- IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairmentNeurology, 2012
- International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancerThe Lancet Oncology, 2011
- Paraneoplastic Neurologic Syndrome in the PNS Euronetwork DatabaseArchives of Neurology, 2010
- Paraneoplastic syndromes of the CNSThe Lancet Neurology, 2008
- Paraneoplastic Syndromes Involving the Nervous SystemNew England Journal of Medicine, 2003